Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
abbvie
4
×
alzheimer's disease
4
×
biotech
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
cancer
4
×
detroit blog main
detroit top stories
eli lilly
indiana blog main
indiana top stories
life sciences
4
×
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
4
×
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
startups
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
clinical trials
merck
astrazeneca
biogen
boehringer ingelheim
bristol-myers squibb
cancer immunotherapy
crispr
What
bio
roundup
4
×
drug
week
companies
debut
moves
acquisitions
alzheimer’s
annual
approval
assessed
attention
biggest
biogen’s
biopharmaceutical
biotech
black
build
buy
ceo
communities
company’s
conference
continue
convo
daniel
diamond
diamond’s
dyne’s
earlier
esmo
europe
failures
germany
gilead
hosted
indication
investment
leading
Language
unset
Current search:
roundup
×
cancer
×
abbvie
×
" life sciences "
×
" san diego top stories "
×
" alzheimer's disease "
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More